Trial · NCT06029595
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Asthma exacerbation over 52 weeks of treatment | Over 52 weeks | Number of Asthma exacerbation over 52 weeks of treatment (Asthma exacerbations defined as severe event with worsening of asthma requiring at least 3 days of SCS use with or without emergency visit or hospitalization) |
| Secondary | Time to first asthma exacerbation; | Up to 52 weeks | Asthma exacerbations defined as severe event with worsening of asthma requiring at least 3 days of SCS use with or without emergency visit or hospitalization |
| Secondary | Number of asthma exacerbation and asthma worsening over 52 weeks of treatment | Up to 52 weeks | Asthma exacerbations defined as severe event with worsening of asthma requiring at least 3 days of SCS use with or without emergency visit or hospitalization; Asthma worsening defined as moderate asthma exacerbation. |
| Secondary | Time to first asthma exacerbation or asthma worsening | Up to 52 weeks | Asthma exacerbations defined as severe event with worsening of asthma requiring at least 3 days of SCS use with or without emergency visit or hospitalization; Asthma worsening defined as moderate asthma exacerbation. |
| Secondary | ACQ-7 responders | week 4, week 26 and week 52 | ACQ-7 responders at Week 4, Week 26 and Week 52 (i.e., subjects showing improvement from baseline in ACQ-7 score of ≥0.5 units); |
| Secondary | Change from baseline in ACQ-7 and ACQ-6 | week 4, week 26 and week 52 | Change from baseline in ACQ-7 and ACQ-6 at Week 4, Week 26 and Week 52 |
| Secondary | Change from baseline in Mini-AQLQ | week 4, week 26 and week 52 | Change from baseline in Mini-AQLQ at Week 4, Week 26 and Week 52 |
| Secondary | Change from baseline in pre-dose FEV1 | week 4, week 26 and week 52 | Change from baseline in pre-dose FEV1 at Week 4, Week 26 and Week 52; |
| Secondary | Change from baseline in pre-dose FVC | Week4, Week 52 and Week 26 | Change from baseline in pre-dose FVC at Week4, Week 52 and Week 26; |
| Secondary | Change from baseline (run-in period) to each inter-visit period and to the entire treatment period in pre dose morning/evening PEF; | Up to 52 weeks | |
| Secondary | Change from baseline to each inter-visit period and to the entire treatment period in the average rescue medication use (number of puffs/day) and asthma symptoms score | Up to 52 weeks | |
| Secondary | Change from baseline to each inter-visit period and to the entire treatment period in the percentage of rescue medication-free days, asthma symptoms-free days and asthma control days. | Up to 52 weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06029595/registered